Despite the considerable morbidity and mortality associ-ated with hypertrophic
cardiomyopathy (HCM), proven therapeutic modalities for this disorder remain limited. The …

Background—Hypertrophic cardiomyopathy patients exhibit myocardial energetic
impairment, but a causative role for this energy deficiency in the pathophysiology of …

Background The presence and extent of left ventricular hypertrophy (LVH) is a major
determinant of symptoms in patients with hypertrophic cardiomyopathy (HCM). There is …

In heart failure with reduced ejection fraction, mechanical work produced by the left ventricle
to support the systemic circulation decreases over time despite relatively constant …

Background—Chronic heart failure (CHF) is a major cause of morbidity and mortality that
requires a novel approach to therapy. Perhexiline is an antianginal drug that augments …

Energy depletion has been highlighted as an important contributor to the pathology of
hypertrophic cardiomyopathy (HCM), a common inherited cardiac disease. Pharmacological …

Background: Perhexiline, originally used as a first-line prophylactic antianginal agent, is now
regarded primarily as a treatment for otherwise refractory myocardial ischemia. Recent …

Objectives: The aim of this study was to determine whether short-term treatment with
perhexiline improves cardiac energetics, left ventricular function, and symptoms of heart …

Approaches to the pharmacotherapy of angina pectoris have previously centred on the
concept that a transient imbalance between myocardial oxygen “demand” and supply within …

Introduction: The re-purposing of the anti-anginal drug perhexiline (PHX) has resulted in
symptomatic improvements in heart failure (HF) patients. The inhibition of carnitine …